We are international
Donate
TEXT SIZE   


Advocacy Update
March 2016
03.17.16
?
  Donate Facebook Twitter Myeloma Minute  

CMS Releases New Coverage Decision on Allogeneic Transplants

The multiple myeloma community received good news last month when the Center for Medicare and Medicaid Services (CMS) announced they were modifying their National Coverage Determination for allogeneic stem cell transplants. The new determination states that allogeneic stem cell transplants will be covered by Medicare for patients with stage II or III myeloma and who are participating in a clinical trial.

The trials must be focused on studying the comparative effectiveness of treatments, with a specific focus on looking at outcomes related to host vs. graft, other transplant related adverse events, overall survival and quality of life. Previously, CMS did not cover allogeneic transplants under any circumstances. To read the National Coverage Determination, click here. And if you have any questions, please email advocacy@myeloma.org.

Educational Resources

Affordable Care Act FAQ

Medicare and the Affordable Care Act

Multiple Myeloma Insurance Questionnaire

Upcoming Webinar

Please join the advocacy team for our upcoming webinar titled, NIH Funding: How it Benefits You as Patient. The webinar will be held on April 13, 2016 at 7:00 eastern and will focus on the importance of advocating for research funding at the National Institutes of Health (NIH), specifically how certain programs, such as grants for young, emerging researchers and funding for clinical trials, impact myeloma patients . Also discussed will be how you can get involved in advocacy activities to help increase funding and spur new advances in scientific research that will benefit you as a patient. More details are forthcoming. Please click here to register for the webinar.

Take Action on Federal Legislation

Support Oral Parity in the Senate

Support Oral Parity in the House 

Part D Beneficiary Appeals Fairness Act

Increase NIH Funding

Support National Myeloma Awareness Month 

IMF Advocacy Meets Legislators on the Hill

In late February, members of the IMF Advocacy team met with several key legislators on the Hill as representatives from the Patients Equal Access Coalition (PEAC), a collection of patient advocacy organizations, provider groups, and pharmaceutical companies that work collaboratively on treatment access issues for patients at the federal level. The purpose of these meetings was to urge support of the federal oral parity legislation in the House and Senate, H.R. 2739 and S.1566, respectively.

As a result of the efforts of the various organizations involved in the PEAC Hill Day, H.R. 2739 currently sits at 45 cosponsors, while S. 1566 has 8 cosponsors. Both bills have equal bipartisan support between Democrats and Republicans. The Advocacy team continues to work closely with offices on the Hill to garner more support for the legislation and will keep you abreast of any changes that may occur. You can ask your Congressional representatives for their support by sending them an email through our Action Center.

Additional Resources

SPEAC

PEAC

Oral Chemo Parity Map

Check Out Our New Facebook Pages!

Want to know more about what the advocacy team is up to? Then go like our new and improved Facebook pages! We have revamped our IMF Advocacy page and are debuting pages for our coalitions, PEAC and SPEAC. We will be sharing the latest news on legislation and policies we are tracking and updates on our fight to get oral parity passed at the state and federal levels. Click here for IMF Advocacy, here for PEAC and here for SPEAC. Please like them TODAY and ask your Facebook friends to do the same!

Fun Facts!

On this day in 1912, First Lady Taft planted the 1st cherry blossom tree in D.C. This year's festival runs from March 20-April 17.


 related articles